Response to barium selenate supplementation in sheep kept at pasture in the Mediterranean area.
This work evaluated the efficacy of barium selenate supplements in the prevention of disorders related to Se deficiency in sheep maintained at pasture in the Mediterranean area. Ewes on five farms were divided into two equal groups of 1,750 animals: a) the treated group and b) the control group. The animals of the treated group were injected subcutaneously, in the first third of gestation, with a barium selenate compound at a dose of 1 mg Se/kg. The ewes in the control group did not receive any supplement of Se and/or vitamin E. The two groups were managed under the same feeding and husbandry practices throughout the experiment. After lambing, blood glutathione peroxidase (GSHPx) and serum aspartate aminotransferase (AST), creatine kinase (CK) and lactate dehydrogenase (LDH) activities were measured in the lambs born to both group. Blood GSHPx activity was higher in the treated animals, with statistically significant differences due to the response to injection of barium selenate. Mean global serum activities of AST and CK tended to be higher in the control group, as a consequence of the protection given to the treated group by the supplement, but the differences were not statistically significant. This was possibly due to the absence of clinical cases of nutritional myodystrophy (NMD) in the animals of the control group. Therefore it can be stated that barium selenate supplementation can prevent Se deficiency in sheep herds maintained at pasture in this area.
Andrés
S
S
Departamento de Medicina y Sanidad Animal, Facultàd de Veterinaria, Cáceres, Spain. patmedve@unex.es
Mañé
M C
MC
Sánchez
J
J
Barrera
R
R
Zaragoza
C
C
Jiménez
A
A
D000821:Animal Feed / Q000592:standards; D000818:Animals; D000831:Animals, Newborn / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D017609:Barium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D015994:Incidence; D007279:Injections, Subcutaneous / Q000662:veterinary; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008431:Maternal-Fetal Exchange; D019083:Mediterranean Region / Q000453:epidemiology; D009135:Muscular Diseases / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D011247:Pregnancy; D064586:Selenic Acid; D012643:Selenium / Q000172:deficiency*; D018036:Selenium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012756:Sheep; D012757:Sheep Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D014810:Vitamin E / Q000008:administration & dosage / Q000494:pharmacology
D017609:Barium Compounds; D003692:Delayed-Action Preparations; D018036:Selenium Compounds; D014810:Vitamin E; D007770:L-Lactate Dehydrogenase; D005979:Glutathione Peroxidase; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D012643:Selenium; D064586:Selenic Acid; C042078:barium selenate